The current results strongly support the suggestion that loss of miR expression may account for the DNMT3b-mediated hypermethylation defect among breast cancer cell lines that is characterized by methylation-dependent loss expression of methylation-sensitive biomarker genes. The gene discussed is DNMT3B; the disease is breast carcinoma.